[Source: Lancet HIV, full page: (LINK). Abstract, edited.]
Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models
Britta L Jewell, PhD †, Edinah Mudimu, PhD †, John Stover, PhD †, Debra ten Brink, MD †, Prof Andrew N Phillips, PhD †, Jennifer A Smith, DPhil, Rowan Martin-Hughes, PhD, Yu Teng, PhD, Robert Glaubius, PhD, Severin Guy Mahiane, PhD, Loveleen Bansi-Matharu, PhD, Isaac Taramusi, PhD, Newton Chagoma, PhD, Michelle Morrison, PhD, Meg Doherty, PhD, Kimberly Marsh, PhD, Anna Bershteyn, PhD, Prof Timothy B Hallett, PhD, Sherrie L Kelly, PhD, for the HIV Modelling Consortium
Open Access | Published: August 06, 2020 | DOI: https://doi.org/10.1016/S2352-3018(20)30211-3
The COVID-19 pandemic could lead to disruptions to provision of HIV services for people living with HIV and those at risk of acquiring HIV in sub-Saharan Africa, where UNAIDS estimated that more than two-thirds of the approximately 38 million people living with HIV resided in 2018. We aimed to predict the potential effects of such disruptions on HIV-related deaths and new infections in sub-Saharan Africa.
In this modelling study, we used five well described models of HIV epidemics (Goals, Optima HIV, HIV Synthesis, an Imperial College London model, and Epidemiological MODeling software [EMOD]) to estimate the effect of various potential disruptions to HIV prevention, testing, and treatment services on HIV-related deaths and new infections in sub-Saharan Africa lasting 6 months over 1 year from April 1, 2020. We considered scenarios in which disruptions affected 20%, 50%, and 100% of the population.
A 6-month interruption of supply of antiretroviral therapy (ART) drugs across 50% of the population of people living with HIV who are on treatment would be expected to lead to a 1·63 times (median across models; range 1·39–1·87) increase in HIV-related deaths over a 1-year period compared with no disruption. In sub-Saharan Africa, this increase amounts to a median excess of HIV deaths, across all model estimates, of 296 000 (range 229 023–420 000) if such a high level of disruption occurred. Interruption of ART would increase mother-to-child transmission of HIV by approximately 1·6 times. Although an interruption in the supply of ART drugs would have the largest impact of any potential disruptions, effects of poorer clinical care due to overstretched health facilities, interruptions of supply of other drugs such as co-trimoxazole, and suspension of HIV testing would all have a substantial effect on population-level mortality (up to a 1·06 times increase in HIV-related deaths over a 1-year period due to disruptions affecting 50% of the population compared with no disruption). Interruption to condom supplies and peer education would make populations more susceptible to increases in HIV incidence, although physical distancing measures could lead to reductions in risky sexual behaviour (up to 1·19 times increase in new HIV infections over a 1-year period if 50% of people are affected).
During the COVID-19 pandemic, the primary priority for governments, donors, suppliers, and communities should focus on maintaining uninterrupted supply of ART drugs for people with HIV to avoid additional HIV-related deaths. The provision of other HIV prevention measures is also important to prevent any increase in HIV incidence.
Bill & Melinda Gates Foundation.
Keywords: SARS-CoV-2; COVID-19; HIV/AIDS; Africa.